Latest News - Kala Pharmaceuticals

Monday, November 13, 2017 | Management/Leadership, Kala Pharmaceuticals

Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer

Kala Pharmaceuticals announced the appointment of Todd Bazemore as Chief Operating Officer of the company. He will report directly to Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmace…

Read the full story

Wednesday, October 25, 2017 | Cataract Surgery, Clinical Trials, Kala Pharmaceuticals

Kala Pharmaceuticals Submits New Drug Application to FDA for Inveltys

Kala Pharmaceuticals announced that it has submitted a new drug application (NDA) to the FDA for Inveltys (KPI-121 1%), a topical twice-a-day product candidate for the treatment of inflammation and pa…

Read the full story

Wednesday, July 26, 2017 | Earnings & Financials, Kala Pharmaceuticals

Kala Pharmaceuticals Announces Close of Initial Public Offering and Exercise of Underwriters’ Option

Kala Pharmaceuticals announced the closing of its initial public offering of 6,900,000 shares of common stock, including the underwriters’ exercise in full of their option to purchase an additio…

Read the full story

Thursday, July 20, 2017 | Earnings & Financials, Kala Pharmaceuticals

Kala Pharmaceuticals Announces Pricing of Initial Public Offering

Kala Pharmaceuticals announced that is has priced its initial public offering of 6,000,000 shares of its common stock at a public offering price of $15 per share, for aggregate gross proceeds of appro…

Read the full story

Monday, May 01, 2017 | Clinical Trials, Kala Pharmaceuticals

Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery

Kala Pharmaceuticals announced positive topline results from its confirmatory phase 3 trial of KPI-121 1% for the treatment of inflammation and pain in patients who have undergone cataract surgery. KP…

Read the full story